Allergan settles with Zydus and Cadila over Delzicol: 4 things to know

Dublin, Ireland-based Allergan Pharmaceuticals settled litigation over its Delzicol prescription used to treat ulcerative colitis.

Advertisement

Here’s what you should know.

1. Allegan settled with Pennington, N.J.-based Zydus Pharmaceuticals and Ahmedabad, India-based Cadila Healthcare.

2. If approved by the FDA, Zydus and Cadila could market generic versions of Delzicol in the United States beginning March 1, 2020.

3. No details regarding the statement were available.

4. Allergan’s stocks opened at $190.40 on Dec. 2, 2016 and closed at $189.71. At noon on Dec. 5, 2016 the stock was up to $190.24.

More articles on gastroenterology/endoscopy news:
AGA Patient INFO Center integrates with gMed: 3 notes
Allergan’s GI business grows by 8.2% in Q3 & more — 3 GI company key notes
Valeant, Takeda deal crumbles; Valeant to invest in Salix: 6 things to know 

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.